VK2809

VK2809 is an orally-administered small-molecule thyroid hormone receptor beta (TR-β) selective agonist developed by Viking Therapeutics. It belongs to the same pharmacologic class as resmetirom (Rezdiffra, Madrigal — FDA-approved March 2024 for MASH) and operates through the same general mechanism: selective activation of the TR-β isoform predominantly in liver tissue, driving improvements in hepatic lipid metabolism, reduction in liver fat, and improvements in dyslipidemia markers.

VK2809 is in Phase 2b development. The VOYAGE Phase 2b trial in biopsy-confirmed MASH evaluated VK2809 across multiple dose arms over 52 weeks. Phase 2a data previously showed strong hepatic fat reduction (>50% relative reduction at 12 weeks). A parallel program in homozygous familial hypercholesterolemia (HoFH) is also progressing. Phase 3 advancement decisions and indication prioritization are forward-looking.

Thyroid hormone (T3) has powerful effects on hepatic metabolism — it drives expression of LDL receptors, promotes hepatic triglyceride clearance, increases fatty acid oxidation, and reduces hepatic steatosis. The cardiovascular and other systemic effects of unselective thyroid hormone activation (tachycardia, bone loss, muscle weakness, atrial fibrillation) come predominantly through TR-α activation. TR-β is preferentially expressed in liver tissue and mediates the metabolic benefits without the cardiovascular and skeletal side effects.

VK2809 is engineered for both receptor selectivity (TR-β over TR-α) and tissue distribution (liver-selective accumulation through first-pass effects). The combined selectivity profile aims to deliver the hepatic metabolic benefits of thyroid hormone activation without the systemic thyrotoxic effects that have historically derailed thyroid-mimetic development.

Phase 2a study in non-alcoholic fatty liver disease showed VK2809 produced statistically and clinically meaningful reductions in liver fat content (MRI-PDFF) at 12 weeks across multiple dose arms — generally consistent with what resmetirom achieves in its parallel program.

VOYAGE Phase 2b in MASH evaluated longer-term effects on histologic endpoints in biopsy-confirmed MASH patients. Topline data has shown statistically significant improvements in MASH resolution and fibrosis improvement across multiple dose arms.

HoFH program reflects the LDL-lowering side of the thyromimetic mechanism. HoFH patients have severely elevated LDL despite maximal lipid-lowering therapy; the TR-β pathway provides an additional LDL-lowering mechanism through upregulation of LDL receptor expression.

No Phase 3 readouts yet for VK2809. The MASH indication is the most clinically advanced path forward.

VK2809 is the second-most advanced clinical thyromimetic for MASH after resmetirom and represents the strongest evidence that TR-β agonism for metabolic disease is a class effect rather than a single-molecule phenomenon. The Phase 2b data is positive across the MASH and dyslipidemia indications. Phase 3 confirmation will determine whether the class effectively becomes a multi-option category or remains a single-approved-drug niche. For the broader story of thyromimetics in weight loss and metabolic disease specifically, VK2809 is the candidate worth tracking after resmetirom — and the case for combining thyromimetic therapy with GLP-1 receptor agonists rests partly on whether the class delivers on its broader promise.